Fate Therapeutics, Inc. (FATE) Insider Daniel D. Shoemaker Sells 13,225 Shares
Fate Therapeutics, Inc. (NASDAQ:FATE) insider Daniel D. Shoemaker sold 13,225 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.87, for a total transaction of $51,180.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Fate Therapeutics, Inc. (NASDAQ:FATE) traded up 0.49% during midday trading on Tuesday, reaching $4.08. 114,863 shares of the company traded hands. The firm’s market capitalization is $168.97 million. Fate Therapeutics, Inc. has a 12 month low of $1.80 and a 12 month high of $5.68. The firm’s 50 day moving average price is $4.06 and its 200 day moving average price is $3.67.
Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. Fate Therapeutics had a negative net margin of 887.68% and a negative return on equity of 67.01%. The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. On average, analysts expect that Fate Therapeutics, Inc. will post ($0.97) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/17/fate-therapeutics-inc-fate-insider-daniel-d-shoemaker-sells-13225-shares.html.
A number of hedge funds have recently made changes to their positions in FATE. Wells Fargo & Company MN lifted its holdings in Fate Therapeutics by 926.7% during the 1st quarter. Wells Fargo & Company MN now owns 281,111 shares of the biopharmaceutical company’s stock valued at $1,279,000 after purchasing an additional 253,732 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Fate Therapeutics by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 59,510 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 952 shares during the last quarter. Neuberger Berman Group LLC bought a new position in Fate Therapeutics during the 1st quarter valued at about $312,000. Morgan Stanley lifted its holdings in Fate Therapeutics by 9.8% during the 1st quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock valued at $2,783,000 after purchasing an additional 54,615 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Fate Therapeutics by 40.9% during the 1st quarter. Renaissance Technologies LLC now owns 295,700 shares of the biopharmaceutical company’s stock valued at $1,345,000 after purchasing an additional 85,800 shares during the last quarter. 64.27% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on FATE shares. ValuEngine upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research note on Friday, September 8th. Leerink Swann restated an “outperform” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research note on Friday, September 8th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $6.79.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.